Indications
Zynquista is indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ? 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy.
Composition
- Active substance
- sotagliflozin
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Zynquista
- Active substance
- sotagliflozin
- ATC code
- A10
- Therapeutic area
- Diabetes Mellitus, Type 1
- Marketing authorisation holder
- Guidehouse Germany GmbH
- Status
- Withdrawn